Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Floriana Camarda
Observed names:
Camarda Floriana,
Camarda, Floriana,
F Camarda,
F. Camarda
Institutions:
Università Cattolica del Sacro Cuore,
Agostino Gemelli University Polyclinic,
Istituti di Ricovero e Cura a Carattere Scientifico
Observed institutions:
Università Cattolica del Sacro Cuore,
Agostino Gemelli University Polyclinic,
Istituti di Ricovero e Cura a Carattere Scientifico
ORCID:
0000-0002-5206-6867
Observed ORCID:
0000-0002-5206-6867
OpenAlex ID:
A5000969455
PARP Inhibitors Resistance: Mechanisms and Perspectives
2022
·
Elena Giudice
, Marica Gentile
, et al.
·
Cancers
·
104
PDF
Advanced and recurrent endometrial cancer: State of the art and future perspectives
2022
·
Francesca Tronconi
, Camilla Nero
, et al.
·
Critical Reviews in Oncology/Hematology
·
77
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial
2023
·
Sandro Pignata
, Giovanni Scambia
, et al.
·
The Lancet Oncology
·
65
Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids
2023
·
Eleonora Cesari
, Alessandra Ciucci
, et al.
·
Journal of Experimental & Clinical Cancer Research
·
64
PDF
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation
2017
·
M A Calegari
, A Inno
, et al.
·
British Journal of Cancer
·
56
PDF
Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon?
2022
·
L. Musacchio
, C.M. Cicala
, et al.
·
ESMO Open
·
54
PDF
Management of single pulmonary metastases from colorectal cancer: State of the art
2022
·
Marco Chiappetta
, Lisa Salvatore
, et al.
·
World Journal of Gastrointestinal Oncology
·
32
POLE mutations in endometrial carcinoma: Clinical and genomic landscape from a large prospective single‐center cohort
2025
·
Camilla Nero
, Rita Trozzi
, et al.
·
Cancer
·
26
PDF
Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter “SLAVE” Study
2020
·
Alessandro Parisi
, Alessio Cortellini
, et al.
·
Cancers
·
22
PDF
Gut microbiota and its influence on ovarian cancer carcinogenesis, anticancer therapy and surgical treatment: A literature review
2021
·
Elena Giudice
, Vanda Salutari
, et al.
·
Critical Reviews in Oncology/Hematology
·
16
Therapeutic Potential of Tisotumab Vedotin in the Treatment of Recurrent or Metastatic Cervical Cancer: A Short Report on the Emerging Data
2023
·
Veronica Agostinelli
, Lucia Musacchio
, et al.
·
Cancer Management and Research
·
12
Antibody drug conjugates in recurrent or metastatic cervical cancer: a focus on tisotumab vedotin state of art
2024
·
Floriana Camarda
, Mariachiara Paderno
, et al.
·
Therapeutic Advances in Medical Oncology
·
11
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis
2022
·
Lucia Musacchio
, Anna Amela Valsecchi
, et al.
·
Cancer Treatment Reviews
·
11
Clinical, Pathological and Prognostic Features of Rare BRAF Mutations in Metastatic Colorectal Cancer (mCRC): A Bi-Institutional Retrospective Analysis (REBUS Study)
2021
·
Maria Alessandra Calegari
, Lisa Salvatore
, et al.
·
Cancers
·
11
PDF
Gene actionability according to the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) in No Specific Molecular Profile (NSMP) endometrial cancer
2025
·
L. Mastrantoni
, F. Camarda
, et al.
·
ESMO Open
·
9
Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives
2022
·
Lucia Musacchio
, Carlo Maria Cicala
, et al.
·
Frontiers in Oncology
·
8
PDF
Single-cell transcriptome analysis of patient-derived organoids captures inter- and intratumor heterogeneity and uncovers targetable pathways in high grade serous ovarian cancer
2026
·
Marco Pieraccioli
, Alessandra Ciucci
, et al.
·
Drug Resistance Updates
·
7
Chemotherapy Rechallenge or Reintroduction Compared to Regorafenib or Trifluridine/Tipiracil for Pretreated Metastatic Colorectal Cancer Patients: A Propensity Score Analysis of Treatment Beyond Second Line (Proserpyna Study)
2024
·
M.A. Calegari
, I.V. Zurlo
, et al.
·
Clinical Colorectal Cancer
·
7
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors
2023
·
Lucia Musacchio
, Serena Boccia
, et al.
·
International Journal of Gynecological Cancer
·
7
FOLFOX rechallenge versus regorafenib in patients with metastatic colorectal cancer refractory to standard chemotherapy: A retrospective analysis.
2019
·
Maria Alessandra Calegari
, Ina Valeria Zurlo
, et al.
·
Journal of Clinical Oncology
·
7
Actionable mutations in early-stage ovarian cancer according to the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT): a descriptive analysis on a large prospective cohort
2024
·
F. Camarda
, L. Mastrantoni
, et al.
·
ESMO Open
·
5
PDF
Recent progress in the use of pharmacotherapy for endometrial cancer
2022
·
Elena Giudice
, Vanda Salutari
, et al.
·
Expert Opinion on Pharmacotherapy
·
5
Conversion Therapy With Encorafenib and Cetuximab for Chemo-Refractory BRAF V600E-Mutated Liver-Limited Colorectal Cancer Metastasis: The First Case Report
2021
·
Maria Alessandra Calegari
, Brunella Di Stefano
, et al.
·
Clinical Colorectal Cancer
·
4
Tisotumab Vedotin in Cervical Cancer: Current Status and Future Perspectives
2021
·
Elena Giudice
, Floriana Camarda
, et al.
·
touchREVIEWS in Oncology & Haematology
·
4
PDF
Chemotherapy rechallenge or reintroduction (CTr/r), regofenib (REG) and TAS-102 for metastatic pretreated colorectal cancer (mCRC) patients (pts): A propensity score analysis of treatment beyond second-line (PROSERpINA Study).
2019
·
Maria Alessandra Calegari
, Ina Valeria Zurlo
, et al.
·
Journal of Clinical Oncology
·
3
Show more works
View as search
Works count:
99
Citation count:
641
H-index:
11
I10-index:
14
Year
Topic
Type